UBS Group AG Has $2.14 Million Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

UBS Group AG lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 92.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,047 shares of the specialty pharmaceutical company’s stock after selling 497,076 shares during the quarter. UBS Group AG owned about 0.08% of Supernus Pharmaceuticals worth $2,139,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of SUPN. Hantz Financial Services Inc. increased its position in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares during the period. EverSource Wealth Advisors LLC bought a new position in Supernus Pharmaceuticals during the second quarter worth $51,000. Smartleaf Asset Management LLC increased its position in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 268 shares during the period. Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals during the second quarter worth $55,000. Finally, Osaic Holdings Inc. increased its position in Supernus Pharmaceuticals by 211.5% during the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after acquiring an additional 1,328 shares during the period.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $53.00, for a total value of $465,711.00. Following the sale, the director owned 27,277 shares in the company, valued at approximately $1,445,681. The trade was a 24.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the sale, the chief executive officer owned 958,100 shares in the company, valued at $48,259,497. This represents a 3.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 116,406 shares of company stock worth $5,911,086. Corporate insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $46.64 on Thursday. The firm has a market capitalization of $2.71 billion, a PE ratio of -91.45, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. The company’s fifty day moving average price is $49.84 and its two-hundred day moving average price is $49.58. Supernus Pharmaceuticals, Inc. has a 52-week low of $30.83 and a 52-week high of $59.68.

Analyst Ratings Changes

A number of equities analysts recently issued reports on SUPN shares. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.